Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
14 ^USD	+8.11%		+11.38%	-35.39%

Apr. 18	TD Cowen Cuts Sage Therapeutics Price Target to $16 From $30, Maintains Buy Rating	MT
Apr. 18	Scotiabank Cuts Price Target on Sage Therapeutics to $19 From $34, Maintains Sector Outperform Rating	MT

Sage Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

November 02, 2021 at 07:22 am EDT

Sage Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 130.17 million compared to USD 105.74 million a year ago. Basic loss per share from continuing operations was USD 2.21 compared to USD 2.03 a year ago. Diluted loss per share from continuing operations was USD 2.21 compared to USD 2.03 a year ago. For the nine months, net loss was USD 333.18 million compared to USD 368.82 million a year ago. Basic loss per share from continuing operations was USD 5.69 compared to USD 7.1 a year ago. Diluted loss per share from continuing operations was USD 5.69 compared to USD 7.1 a year ago.

Latest news about Sage Therapeutics, Inc.

TD Cowen Cuts Sage Therapeutics Price Target to $16 From $30, Maintains Buy Rating	Apr. 18	MT
Scotiabank Cuts Price Target on Sage Therapeutics to $19 From $34, Maintains Sector Outperform Rating	Apr. 18	MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $17 From $25, Maintains Perform Rating	Apr. 18	MT
Top Midday Decliners	Apr. 17	MT
BofA Securities Downgrades Sage Therapeutics to Underperform From Neutral, Adjusts Price Target to $14 From $24	Apr. 17	MT
Sector Update: Health Care Stocks Advance Premarket Wednesday	Apr. 17	MT
Sector Update: Health Care	Apr. 17	MT
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	Apr. 17	MT
Transcript : Sage Therapeutics, Inc. - Special Call	Apr. 17
Top Premarket Decliners	Apr. 17	MT
Sage Therapeutics' Phase 2 Study of Dalzanemdor Fails to Meet Primary Endpoint	Apr. 17	MT
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease	Apr. 17	CI
JPMorgan Raises Price Target on Sage Therapeutics to $29 From $24, Maintains Overweight Rating	Mar. 26	MT
Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board	Mar. 26	CI
Deutsche Bank Adjust Sage Therapeutics Price Target to $18 From $21, Maintains Hold Rating	Feb. 15	MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $25 From $23, Maintains Perform Rating	Feb. 15	MT
RBC Raises PT on Sage Therapeutics to $26 From $21, Says Early Metrics From Zurzuvae Launch Suggest Promising Signs; Keeps Sector Perform, Speculative Risk	Feb. 15	MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	Feb. 14	MT
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines	Feb. 14	MT
Transcript : Sage Therapeutics, Inc., Q4 2023 Earnings Call, Feb 14, 2024	Feb. 14
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Earnings Flash (SAGE) SAGE THERAPEUTICS Posts Q4 Revenue $78M, vs. Street Est of $61M	Feb. 14	MT
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14	CI
Wedbush Adjusts Sage Therapeutics' Price Target to $24 From $22, Keeps Neutral Rating	Jan. 29	MT
Sage Therapeutics, Inc. Enters into Lease Agreement with 55 Cambridge Parkway, LLC	Jan. 24	CI

Chart Sage Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.

Sector

Biotechnology & Medical Research

Calendar

06:30am - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Sage Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

14 USD

Average target price

24.39 USD

Spread / Average Target

+74.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SAGE THERAPEUTICS, INC.	-35.39%	841M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs